Ranking

Cheapest Online Tirzepatide Providers: Every Route, Ranked by Annual Cost

Ranked on what twelve months costs rather than the first month. With coverage, a brand GLP-1 commonly lands near $25 a month and beats every route here. Without it, brand

Rank on the annual figure, not the advertised one

Most rankings of online tirzepatide providers sort by the lowest number on the pricing page. That number is usually a starting dose, a first month, a prepaid year, or a microdose — and often more than one at once.

Here is the same field sorted by what twelve months costs following the label's titration schedule.

A dose-tiered programme advertising $129 can finish the year above a flat programme advertising $186. That reordering is the entire point of this table.

Check coverage before anything on this page

The two cheapest rows are insurance routes, and they beat every self-pay option by a wide margin. Most people comparing compounded providers have never established whether they had a covered option.

Weight-management coverage is excluded far more often than diabetes coverage for the same molecules, and employer plans commonly carve it out as a category. Ask about your indication, not the drug name. Our insurance guide sets out the four questions, and the appeal guide covers what to do when the answer is no.

The brand route is closer than it used to be

Brand Zepbound through LillyDirect is $299 at the starting dose and $449 at higher doses. That is an FDA-approved product with a published trial programme, and it is now within reach of several compounded programmes once they reach a maintenance dose.

One caveat worth knowing: the self-pay rates on the highest doses are reported to be contingent on refilling within a 45-day window, with the manufacturer listing $499 at 7.5 mg and $699 at 10, 12.5 and 15 mg outside it. If your schedule is irregular, that is a real risk to the saving.

Mounjaro is the same molecule and the wrong purchase

Mounjaro and Zepbound are both tirzepatide. The difference is the approved indication: Mounjaro for type 2 diabetes, Zepbound for weight management. There is no manufacturer self-pay programme for Mounjaro at weight-loss doses, and telehealth providers list it near retail at $1,100 to $1,899 a month.

If you are paying cash and want tirzepatide, Zepbound is the same molecule at a fraction of the price. Mounjaro makes financial sense only with coverage and a type 2 diabetes diagnosis.

What we actually hold, and what we withdrew

Figures we captured at the source ourselves

Seven records. That is the entire set of tirzepatide prices this publication has read at source. Every other figure on the internet for this market is somebody else's capture, or nobody's.

The ten figures we withdrew, and why

Why this happened, in plain terms

We spent several pages criticising other publications for quoting prices without their term, dose and formulation. Then we republished their figures without checking any of the three.

Our evidence model has a status called reported, which means the provider reported it. We applied it to figures no provider had reported to anyone — they were things other websites had written. That is not a labelling nicety. It is the difference between a price and a rumour.

A new status now exists, third-party claim, and figures carrying it cannot be ranked, summed, averaged or compared anywhere on this site. The Embody case shows why: a single number, republished across at least five publications, that does not survive one search.

If you want a figure for any provider below, the honest answer is that you should read it on their own pricing page, on the plan you would sign, at the dose you expect to reach. That is what we did for the seven records above and have not yet done for the rest.

The question that settles it

Whatever route you are considering, one question does most of the work: what is the all-in monthly price at 10 mg, on the plan I would actually sign? Everything above is an attempt to answer that for a market where most providers do not publish it.

Questions readers actually ask

Capture standing: 15 of 70 price records in this dataset were read at the source by us: 9 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.